Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (5)

2023

  1. Disease-modifying treatments for patients with multiple sclerosis in Spain

    Farmacia Hospitalaria, Vol. 47, Núm. 4, pp. 155-160

  2. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

2022

  1. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2019

  1. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Breast Cancer Research, Vol. 21, Núm. 1

2018

  1. Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii64